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Abstract
Background: We conducted a systematic review and meta-analysis to obtain a reliable estimation of the
prevalence of osteoporosis in China and to characterize its epidemiology.
Methods: We identified relevant studies via a search of literature published from 2003 to October 2015 in the
PubMed, Web of Science, China National Knowledge Infrastructure, Wanfang and Weipu databases. Both Chinese
and WHO criteria were considered acceptable for the diagnosis of osteoporosis. Prevalence estimates were
obtained using random effects models. Meta-regression analysis was used to explore the sources of heterogeneity,
and publication bias was evaluated by visually inspecting funnel plots.
Results: Overall, 69 articles were included in this study. An obvious increase in the prevalence of osteoporosis was
identified over the past 12 years (prevalence of 14.94 % before 2008 and 27.96 % during the period spanning
2012–2015). The prevalence of osteoporosis was higher in females than in males (25.41 % vs. 15.33 %) and
increased with age. Osteoporosis prevalence was higher in rural than in urban areas (20.87 % vs. 23.92 %) and
higher in southern than in northern areas (23.17 % vs. 20.13 %). At present, the pooled prevalence of osteoporosis
in people aged 50 years and older was more than twice the pooled prevalence identified in 2006 (34.65 % vs. 15.
7 %). The application of different diagnostic criteria could have an impact on prevalence estimation (19.7 % vs. 29.
3 %). Meta-regression suggested that study setting also influenced the estimation of point prevalence (P = 0.022).
Conclusions: The prevalence of osteoporosis in China has increased over the past 12 years, affecting more than
one-third of people aged 50 years and older. The prevalence of osteoporosis increased with age and was higher in
females than in males. Prevention and control measures have become all the more important given the increase in
osteoporosis prevalence, and three-step prevention programmes should be implemented.
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Background
Osteoporosis is a metabolic disease associated with de-
creased bone strength and characterized by bone mass re-
duction, increased skeletal fragility and bone tissue
structure deterioration [1]. Osteoporosis is the most fre-
quent cause of bone fractures in the elderly, especially
spine, proximal femur (hip), distal forearm, and proximal
humerus fractures [2]. Typically, symptoms do not appear
until the occurrence of a broken bone, and even minor
stress may induce fractures when bone mineral density
(BMD) is decreased. Chronic pain caused by osteoporosis
has been found to severely interfere with normal activities
[3]. In developed countries, the prevalence of osteoporosis
ranges from 2 to 8 % among males and 9 to 38 % among
females depending on the method of diagnosis [4]. It has
been reported that approximately 2 million males and 8
million females above the age of 50 years in the United
States have been diagnosed with osteoporosis, and 34 mil-
lion people are estimated to have osteopenia [5]. Approxi-
mately 5.5 million men and 22 million women in Europe
were affected by osteoporosis in 2010 [6]. Although the
exact rates of osteoporosis remain unclear [7], this condi-
tion is becoming an urgent health concern worldwide. In
addition to increasing activity restriction and the risk of
fragility fractures, osteoporosis may increase the risk of
hospitalization associated with some complications, and
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thus imposes a huge economic burden on the public
health system [8]. Using hip fractures as an example, hip
fractures have been estimated to be associated with a 10
to 20 % increase in mortality, and an estimated 25 % of
people with hip fractures in the United States need long-
term home nursing care [9]. The cost of each hip fracture
was estimated to be $34,000 to 43,000, and the annual
cost of all osteoporosis-related fractures is estimated to
reach 18 billion dollars [10].
It is foreseeable that China may face a similarly severe
health problem in the future. This is apparent due to
two main reasons. One reason is the huge population
that may result in a large population of people with
osteoporosis in China. The other reason is that the age-
ing population may be associated with increased pension
and healthcare costs, forcing large increases in public
spending, as advanced age is one of the main risk factors
for osteoporosis [11]. The most recent nationwide osteo-
porosis survey, conducted in 2006, showed that the
prevalence rates of osteoporosis among those above the
age of 50 years were 57.6 % in males and 64.6 % in fe-
males. Almost 10 years have passed since this survey.
Previous studies have focused more on determining ref-
erence values of BMD and were conducted before 2008
[12, 13]. A reliable estimate of osteoporosis prevalence is
necessary in countries such as China. This estimate may
have a particularly practical significance in providing
guidance for the control and prevention of osteoporosis.
As China has a huge population, even modest progress
in the preventive management of osteoporosis can sig-
nificantly improve population level health outcomes. For
these reasons, we conducted a systematic review and
meta-analysis to reliably estimate the prevalence and
characterize the epidemiology of osteoporosis in China.
Methods
An ethical statement is not needed for this study because
this is a meta-analysis and systematic review based on
published studies. We conducted this meta-analysis and
systematic review in accordance with the 2009 PRISMA
(Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) guidelines [14].
Search strategy
We conducted electronic searches of the PubMed, Web
of Science, CNKI (China National Knowledge Infrastruc-
ture), Wanfang (Chinese) and Weipu (Chinese) data-
bases to identify population-based studies that measured
the prevalence of osteoporosis from inception until
October 2015. These searches used free text and medical
subject heading terms and combined osteoporosis-
related keywords. Search terms included ‘osteoporosis’,
‘osteopenia’, ‘OP’, ‘bone mineral density’, ‘brittle-bone dis-
ease’, ‘bone’, ‘prevalence’, ‘cross-sectional’, ‘epidemiology
survey or investigation’, ‘China’, and ‘Chinese’. Language
of publication was restricted to English and Chinese. We
also retrieved the reference lists of included articles and
previous reviews to identify potential studies as compre-
hensively as possible. Studies were restricted to those
evaluating the Chinese population.
Criteria for inclusion
The inclusion criteria are listed as follows:
1. Study population: Participants were aged ≥15 years
and included a representative sample of Chinese
population or mixed population, and the study was
conducted in a geographically defined or clinical
setting.
2. Period: The time period of the study was restricted
to the period from January 2003 to October 2015.
3. Study type: Data from cross-sectional studies or
baseline investigations from prospective studies with
defined osteoporosis diagnosis criterion were in-
cluded (Additional file 1).
4. Information: Studies including metrics for sample
size and directly and/or indirectly providing
prevalence of osteoporosis with or without age-
specific estimates were included.
Criteria for exclusion
Studies conducted in a population with specific other
diseases or occupations were excluded (connective tissue
disease, gastrointestinal and nutritional diseases, endo-
crine and metabolic diseases, haematological system dis-
eases, and a population working in an environment with
lead, cadmium and aluminium). Studies with sample
sizes smaller than 100 participants were excluded. Re-
views, commentaries, and case reports were also
excluded.
Data extraction
Two investigators (CP and LZZ) independently extracted
data using a standardized data collection sheet. Dis-
agreements were resolved through discussion with team
members. The following information was collected from
each study: year of publication, year in which the study
was conducted, first author, province, study design, area
(northern or southern), region (urban or rural), mini-
mum age of participants, number of osteoporosis cases
and sample size, response rate of the survey, method of
sample selection, source of sample, diagnostic criteria
(World Health Organization (WHO) or Chinese), equip-
ment used for BMD measurement, and study quality
score. We also contacted the authors of an article if ne-
cessary. The outcome of interest was the prevalence rate
of osteoporosis in different settings.
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Quality assessment
The quality of each included study was assessed using the
quality assessment criteria for observational studies rec-
ommended by the Agency of Healthcare Research and
Quality. These assessment criteria include 11 criteria with
three potential responses: Yes, No and Unclear. Briefly,
the 11 criterion are as follows: 1: Does the study define
the information source of the survey? 2: Does the study
report clear inclusion or exclusion criteria? 3: Does the
study report the time period of patient inclusion? 4: Was
the study population enrolled consecutively? 5: Does the
study indicate whether the evaluators of subjective com-
ponents were blind to other aspects of participant status?
6: Was any quality control conducted? 7) Does the study
describe the excluded patients in detail? 8: Does the study
indicate whether the models included adjustment for po-
tential confounders? 9) How did the authors address miss-
ing data, if applicable? 10: Does the study summarize
patient response rates and completeness of data collec-
tion? 11: Does the study describe follow-up and the esti-
mated percentage of incomplete data? A maximum score
of 11 was possible for each study. A score ≤5 points was
considered as low quality [15].
Statistical analysis
We estimated the prevalence rates of osteoporosis with
95 % confidence intervals (CIs) overall and by subgroup.
The point prevalence rates were first transformed into arc-
sine square root transformed proportions. The trans-
formed data were fitted for a random effects model using
DerSimonian-Laird weights, and studies with 0 cases were
still included in the overall analysis [16]. Heterogeneity
across studies was examined using Cochran chi-square
(χ2) tests. The classification of heterogeneity depended on
the I2 statistic: < 25 % indicated a low level, 25–50 % indi-
cated a moderate level, and >50 % indicated a high level of
heterogeneity [17]. We adopted a random effects model to
estimate the prevalence of osteoporosis and performed
subgroup analyses by year of data collection (before 2008,
2009–2011, and 2012–2015), region (urban and rural),
area (South and North China), age at onset (15–24, 25–
35, 46–49, and 50- years), gender (female and male), age
group (15-, 30-, 40-, 50-, 60-, 70-, 80- years) overall and
separately for males and females, and diagnostic criteria
(WHO vs. Chinese). The categorization of year of data
collection was based on the distribution of the number of
studies; age at onset was categorized based on the
categorization and lack of specific ages within the included
studies. To explore the main factors influencing preva-
lence estimation and sources of heterogeneity, we con-
ducted meta-regression analysis including the following
covariates: year of publication, year of data collection, fe-
male ratio (%), area, source, response rate, region, criter-
ion, age at onset, and quality score. Publication bias was
evaluated by inspecting Begg’s funnel plots with log preva-
lences and standard errors. Begg’s Test and Egger’s Test
were also used for qualitative judgements of bias. P < 0.05
was considered statistically significant.
Results
The preferred reporting items for this systematic review
and meta-analysis are presented in Additional file 2.
Study selection and characteristics
The flow chart for study selection is presented in Fig. 1. In
brief, our initial searches identified 1798 records. After
title and abstract screening, 606 duplicates were removed,
and 1062 records were excluded for different reasons; fol-
lowing this exclusion, 130 full-texts were assessed using
the inclusion criteria. Finally, 69 studies (Additional file 3)
were included in qualitative and quantitative synthesis.
The characteristics of the 69 included studies are
shown in Additional file 4. The studies were published
between 2003 and 2015. Of the 69 studies, 50 had been
conducted in urban areas and 19 had been conducted in
rural areas; 36 studies were conducted in South China
and 33 were conducted in North China; 39 studies eval-
uated osteoporosis based on the WHO diagnostic cri-
teria and 30 evaluated osteoporosis based on Chinese
criteria; and 53 and 56 studies focused on males and fe-
males, respectively. The sample size per study ranged
from 179 to 19,609, and the total population included in
this meta-analysis was 184,100 participants, including
75,710 males and 108,390 females. The total number of
included participants was not equal to the sum of num-
bers of males and females because some studies only
provide total numbers and did not separate participants
into males and females. The point prevalence of osteo-
porosis varied from 1 to 86 %. Except one cohort study,
most studies had a cross-sectional design. The survey re-
sponse rates were mostly above 90 %. The response rates
ranged from 85.9 to 100.0 % with a mean of 96.6 %. The
quality scores of four studies were less than five points
because of insufficient sample sizes. The overall quality
of the included studies was acceptable.
Pooled prevalence rates of osteoporosis
Overall
The meta-analysis of the total prevalence estimates of stud-
ies evaluating participants with an onset age of 15–24 years
(n = 29, N = 97,997) showed that the prevalence rate of
osteoporosis was 16.96 % (95 % CI: 13.26–21.02 %, Fig. 2,
Table 1) with a high level of heterogeneity (99.6 %). The
prevalence rates of osteoporosis at onset ages of 25–35,
46–39, and 50- years were 28.09 % (95 % CI: 18.11–
39.32 %), 28.04 % (12.11–42.95 %) and 34.65 % (30.30–
44.24 %), respectively. Thus, estimated prevalence rates
increased with age.
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Study year
The meta-analysis results showed a general upward
trend. The prevalence rates among studies with data col-
lected before 2008, from 2009 to 2011, and from 2012 to
2015 were 14.94 % (95 % CI: 10.65–19.8 %), 23.65 %
(17.57–30.35 %) and 27.96 % (19.90–36.81 %), respect-
ively. These data indicated that osteoporosis prevalence
slightly increased from 2009–2011 to 2012–2015; how-
ever, the prevalence during both of these time periods
were obviously higher than the prevalence before 2008.
Sex- and age-specific groups
The prevalence rate of osteoporosis was significantly
higher among females (25.41 %, 95 % CI: 21.54–29.49 %,
Fig. 3) than males (15.33 %, 11.8–19.21 %, Fig. 4)
(Table 1). In all age groups, the prevalence rates of
osteoporosis increased with age. Specifically, the rate
was the lowest (2.40 %) in the 15 to 30-year age group
and the highest (56.10 %) in the 80 years and older age
group in combined populations (6.49 % for 30- years,
8.88 % for 40- years, 19.57 % for 50- years, 35.10 % for
60- years, 43.38 % for 70- years). The prevalence rates
among males (1.12 %, 3.43 %, 6.42 %, 11.64 %, 18.71 %,
28.6 %, 36.53 %) and females (2.18 %, 6.48 %, 10.10 %,
23.85 %, 45.77 %, 58.26 %, 68.45 %) were consistent with
this overall trend. The overall prevalence in females was
higher than the prevalence in males in each age group.
Gender differences in osteoporosis prevalence in differ-
ent regions and areas are shown in Tables 2 and 3. The
prevalence rates in South China were higher among
males than females (26.19 % vs. 17.95 %), while oppos-
ing results were identified in North China (12.22 % vs.
24.61 %). Similar phenomena did not appear in different
regions. The prevalence rates were higher among fe-
males than males regardless of urban (22.96 % vs. 16.47)
or rural (30.98 % vs. 12.15 %) residence. The gender dif-
ference was significant in rural but not in urban areas.
Region and area
The prevalence rate of osteoporosis was slightly but
not significantly lower in urban than in rural areas
(20.87 % vs. 23.92 %; 95 %CI: 17.05–24.96 %).
Fig. 1 Flow diagram of included/excluded studies
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Fig. 2 Forest plot of prevalence of osteoporosis for total people
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Similarly, the prevalence rate was slightly but not sig-
nificantly higher in South China (23.92 %, 95 %
CI: 18.29–28.44 %) than in North China (20.13 %,
15.62–25.06 %).
Diagnostic criteria and source of population
There were some differences (approximately 0.5 SD) in
osteoporosis prevalence between studies using the WHO
and Chinese criteria. The results showed that the pooled
Table 1 Prevalence of osteoporosis according to different items




N I2 (%) Publication bias
P(Begg) P(Egger)
Study year Before 2008 17 14.94 [10.65–19.8] 49824 99.7 0.228 0.493
2009–2011 20 23.65 [17.57–30.35] 74250 99.8 0.003 0.055
2012–2015 16 27.96 [19.90–36.81] 36106 99.5 0.128 0.100
Region Urban 50 20.87 [17.05–24.96] 124462 99.7 0.623 0.050
Rural 19 23.92 [17.17–31.39] 67226 99.8 0.093 0.056
Area Southern 36 23.17 [18.29–28.44] 95814 99.7 0.003 0.000
Northern 33 20.13 [15.62–25.06] 95874 98.7 0.559 0.343
Sex Male 53 15.33 [11.80–19.21] 75710 99.5 0.105 0.379
Female 56 25.41 [21.54–29.49] 108390 99.6 0.072 0.118
Onset age of study(y) 15–24 29 16.96 [13.26–21.02] 97997 99.6 0.053 0.035
25–35 9 28.09 [18.11–39.32] 24122 99.7 0.119 0.069
46–49 20 28.04 [12.11–42.95] 44500 99.7 0.028 0.015
50- 11 34.65 [30.30–44.24] 24969 99.7 0.000 0.019
Age-specific group(y) 15- 27 2.40 [1.32–3.79] 7265 91.1 0.532 0.134
30- 36 6.49 [4.52–8.77] 21541 97.4 0.004 0.157
40- 49 8.88 [7.05–10.90] 43160 97.9 0.0128 0.000
50- 51 19.57 [16.29–23.07] 41983 98.7 0.143 0.169
60- 54 35.10 [29.71–40.42] 36453 99.1 0.172 0.256
70- 45 43.48 [37.69–49.37] 19238 98.5 0.135 0.009
80- 26 56.10 [46.44–65.52] 3827 97.2 0.827 0.027
Male(age) 15- 24 1.12 [0.51–1.97] 3586 73.5 0.001 0.069
30- 30 3.43 [2.25–4.84] 9132 90.4 0.090 0.301
40- 38 6.42 [4.78–8.27] 17055 94.8 0.755 0.240
50- 38 11.64 [9.08–14.47] 14756 96.1 0.044 0.145
60- 38 18.71 [14.90–22.84] 12028 96.7 0.260 0.001
70- 33 28.6 [23.3–34.21] 6740 95.9 0.189 0.862
80- 23 36.53 [27.71–45.82] 1421 91.9 0.601 0.452
Female(age) 15- 22 2.18 [1.06–3.68] 3433 84.4 0.524 0.017
30- 29 6.84 [4.15–10.12] 11530 97.3 0.065 0.016
40- 39 10.10 [7.59–12.92] 23318 97.6 0.037 0.304
50- 39 23.85 [18.93–29.14] 21574 98.7 0.141 0.052
60- 42 45.77 [38.38–53.25] 15226 98.8 0.124 0.323
70- 34 58.26 [49.26–67.00] 7420 98.3 0.032 0.291
80- 22 68.45 [57.83–78.17] 1208 93.2 0.069 0.676
Criteria for diagnostic WHO 39 20.35 [16.01–25.07] 123900 99.7 0.090 0.159
China 30 23.4 [18.56–28.77] 67698 99.6 0.047 0.235
Source of population General 45 19.7 [16.0–22.90] 145985 99.6 0.673 0.467
Hospital 24 29.3 [21.75–36.62] 45703 99.7 0.213 0.503
Chen et al. BMC Public Health  (2016) 16:1039 Page 6 of 11
Fig. 3 Forest plot of prevalence of osteoporosis for female Fig. 4 Forest plot of prevalence of osteoporosis for male
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prevalence obtained from studies using the Chinese cri-
terion was only slightly but not significantly higher than
that obtained from studies using the WHO criteria
(23.4 % vs. 20.35 %). The point estimate for osteoporosis
prevalence obtained in the hospital setting was higher
than that obtained from studies conducted in the general
population (29.3 % vs. 19.7 %).
Meta-regression analysis and publication bias
We observed that the heterogeneity across studies is par-
ticularly high when studies were evaluated overall. The I2
statistics ranged from 73.5 to 99.8 %. In the meta-
regression analyses, overall prevalence estimates were not
modified by the year of publication, female ratio (%), area,
response rate, region, criteria, age at onset, or quality score.
The results showed that year of data collection and study
setting both significantly affected the estimation of point
prevalence (P = 0.048, P = 0.022). Studies conducted in
hospital populations were associated with an overestimated
pooled prevalence of osteoporosis; however, this result does
not fully explain the high level of heterogeneity observed.
We generated a funnel plot including all studies; however,
the funnel plot did not show evidence of asymmetry (Fig. 5).
Analysis using Begg’s and Egg’s tests provided similar re-
sults (P = 0.297, P = 0.300). However, publication bias was
still identified in some subgroups (Table 1).
Discussion
This systematic review and meta-analysis was conducted
to estimate the prevalence rates of osteoporosis among
Chinese males and females, characterize the epidemi-
ology of osteoporosis in China, and compare osteopor-
osis prevalence rates between the Chinese population
and other populations. Several characteristics of osteo-
porosis in China were identified. First, the prevalence of
osteoporosis obviously increased over the past decade
(from a prevalence of 14.94 % before 2008 to 27.96 % in
the period spanning 2012–2015). Second, the prevalence
rate was higher in females than in males of the same age
groups. Third, the prevalence was higher in rural areas
than in urban areas and higher in South China than in
North China. Fourth, at present, the pooled prevalence
of osteoporosis in people above the age of 50 years is es-
timated to be more than twice the pooled prevalence in
2006 (34.65 % vs. 15.7 %) [18]. The prevalence of osteo-
porosis among the Chinese elderly population identified
in this study was very high. Fifth, the application of dif-
ferent diagnostic criteria could have impacted prevalence
estimation.
One of the main risk factors for osteoporosis in both
males and females is ageing, which is a non-modifiable fac-
tor. The Korea National Health and Nutrition Examination
Survey (KNHANES) showed an obvious age difference
[19]. A large-scale survey in Austria indicated that the
prevalence of osteoporosis increased with age [20]. A co-
hort study suggested that participants diagnosed at a young
age had a higher prevalence of osteoporosis than those di-
agnosed at an older age (35 % vs. 10.0 %). It has been
Table 2 Comparison of osteoporosis prevalence for sex in different regions and areas
Category Subgroup NO. of Studies Prevalence (95 % CI)(%) N I2 (%) Publication bias
P(Begg) P(Egger)
Southern Female 29 17.95 [11.79–25.08] 39133 99.7 0.065 0.929
Male 29 26.19 [20.46–32.35] 51945 99.6 0.246 0.145
Northern Female 27 24.61 [19.32–30.31] 56445 99.5 0.348 0.366
Male 23 12.22 [9.28–15.51] 36577 98.8 0.809 0.717
Urban Female 38 22.96 [18.18–28.13] 64926 99.6 0.009 0.001
Male 39 16.47 [11.91–21.61] 52689 99.6 0.007 0.007
Rural Female 17 30.98 [23.98–38.46] 43263 99.6 0.205 0.046
Male 14 12.15 [8.51–16.34] 23222 98.7 0.101 0.021







Year of publication −0.227 −0.086 to 0.002 0.061
Year of collecting −0.239 −0.101 to −0.001 0.048
Female ration (%) 0.171 −0.198 to 1.099 0.170
Area (northern vs
southern)
0.062 −0.217 to 0.364 0.614
Source (Hospital vs
General)
0.276 0.055 to 0.672 0.022
Response rate (%) 0.245 0.000 to 0.059 0.051
Sample size,
continuous
−0.320 −0.001 to 0.001 0.070
Region (Urban vs
Rural)
0.064 −0.226 to 0.386 0.604
Criteria (WHO vs
China)
−0.151 −0.479 to 0.110 0.215
Quality score −0.012 −0.166 to 0.151 0.924
Age of onset 0.200 −0.002 to 0.021 0.099
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recognized that bone mineral density (BMD) decreases with
age after reaching its optimal value. A clinical study includ-
ing 17,083 subjects showed that the rates of bone mass re-
duction among women at 50–64 and ≥65 years of age were
31 and 62 %, respectively [21]. Our study was consistent
with these studies. Sex is another non-modifiable factor.
We found the prevalence rates of osteoporosis were re-
markably higher among females than males in all age
groups. According to a comprehensive review from Iraq,
the prevalence of osteoporosis was 12 % among men, 3 %
among premenopausal women, and 19 % among postmen-
opausal women, suggesting a significant gender difference
[22]. Similar results have been reported in the United States
(4.5 % vs. 15.4 %) [23]. One possible reason for the gender
difference is that the oestrogen deficiency associated with
menopause or oophorectomy may lead to a rapid BMD re-
duction in women, while in men, a decrease in testosterone
levels may have a similar but less pronounced effect. An
animal study showed that androgen receptor-mediated ac-
tion was pivotal to bone maintenance in male mice, and
oestrogens and androgens may regulate bone growth [24].
That could explain why postmenopausal women may be
more prone to osteoporosis [25]. In this meta-analysis, we
did not divide participants into premenopausal and post-
menopausal subgroups. However, we still saw a significant
increase in the prevalence of osteoporosis in females (from
10.1 to 23.85 %). Previous studies have also confirmed that
women are at a higher risk of osteoporosis than men [26].
Another non-modifiable factor is race. We divided the
studies into those conducted in South China and North
China. The prevalence was higher in South China than
North China. However, the prevalence rate among males in
South China was higher than the rate among South Chin-
ese females (26.19 % vs. 17.95 %), and opposing results were
identified in North China (12.22 % vs. 24.61 %). These find-
ings are in contrast with some previous studies. The preva-
lence of osteoporosis in North Iraq was found to be higher
than that in South Iraq, and that regional difference was at-
tributed to differences in vitamin D levels. As has been re-
ported, vitamin D3 synthesis may not be sufficient to
account for BMD reduction due to the lack of ultraviolet
rays in high-latitude regions [27]. In addition to this factor,
eating habits may account for some of the differences in
osteoporosis prevalence in China. People in North China
prefer cooked wheaten food, while people in South China
live on rice and eat more aquatic products. Moreover, the
climate is dry in North China and moist in South China,
which also may account for the different results. However,
the specific mechanism behind this difference is still un-
clear. Diet and lifestyle have been found to be associated
with increased BMD [28]. Additionally, the prevalence of
osteoporosis was slightly higher in rural than urban areas;
this difference was probably due to disparities in health and
medical resources. Osteoporosis is also a genetic disease.
Those with a family history have a higher risk of osteopor-
osis; however, the heritability of BMD reduction has been
found to vary widely from 25 to 80 %, and osteoporosis has
been found to be associated with more than 30 genes [29].
Unlike advanced age, gender and race, eating habits
are a modifiable factor. There are many other modifi-
able risk factors such as smoking, drinking, lower
levels of physical activity, vitamin D deficiency, his-
tory of fracture, and calcium malabsorption [30]. In
addition, China faces two major challenges now and
in the future. First, China has the largest population
in the world, which means an increased population
with osteoporosis even if the incidence of osteopor-
osis is kept at the current level. Second, accelerated
Fig. 5 Funnel plot for publication bias
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ageing in China necessitates the establishment of an
all-functional social security system for the ageing
population. As is well known, people aged 50 and
years and above are at an increased risk of osteopor-
osis. As reported in 2010, there were 111 million
(8.2 % of China’s population) elderly Chinese individ-
uals (aged 65+ years), of which 19.3 million were in
the oldest age group (aged 80+). The elderly popula-
tion aged 65+ years is estimated to increase im-
mensely, reaching 400 million by 2050 [30]. Though
the one-child policy was further loosened in Novem-
ber 2013 after the Third Plenary Session of the 18th
CPC Central Committee, its current form stipulates
that couples are allowed to have two children if one
of them is an only child. However, this change might
result in unintended consequences [31].
Given the current epidemiology of osteoporosis in
China, preventive and control measures are needed to
increase the awareness of citizens regarding this con-
dition through three-step prevention programmes.
Maximization of bone mass is the key to preventing
osteoporosis. According to the present results, osteo-
porosis is an age-related disease. Calcium and vitamin
D supplementation are needed, especially in females
and people aged 50 years and above. People in the
hospital setting were found to have a higher preva-
lence of osteoporosis; however, samples obtained from
the general population may have underestimated the
prevalence of osteoporosis, and more effective screen-
ing methods are needed.
This study has some limitations. First, more females
than males were included, which may have resulted in
an overestimate of the prevalence of osteoporosis, as it
occurs more frequently among females. Second, the
onset ages in the included studies were categorized
differently, which we believe could affect the results in
some subgroups since the point prevalence of osteo-
porosis was found to increase with increased age.
Third, heterogeneity was relatively high in all analyses.
Although we identified one factor affecting these re-
sults, the degree of explainability was very limited.
Nevertheless, the main strengths of this study were
that most of the included studies had large sample
sizes. Two investigators independently extracted data
and reviewed the articles to obtain data accurately.
We report the results in accordance with the PRISMA
statement.
Conclusions
The prevalence of osteoporosis in China has increased over
the past 12 years, affecting more than one-third of the
people aged 50 years and older. The prevalence of osteo-
porosis was found to increase with age and was higher in
females than males. Prevention and control measures have
become more important given the increase in the preva-
lence of osteoporosis.
Additional files
Additional file 1: Table S1. China and international osteoporosis
diagnosis criteria. (DOC 30 kb)
Additional file 2: PRISMA 2009 Checklist. (DOC 64 kb)
Additional file 3: Studies included in the meta-analysis. (DOC 47 kb)
Additional file 4: Characteristic of Studies on the Prevalence of
osteoporosis. (DOC 256 kb)
Abbreviations
IPV: Intimate partner violence
Acknowledgements
We thank all our colleagues working in the Department of Epidemiology
and Health Statistics, School of public health of Central South University.
Funding
There is no funding for this manuscript.
Availability of data and material
All data generated or analyzed during this study are included in this
published article.
Authors’ contributions
CP, HYH and LZZ participated in the design of the study and data collection.
CP and LZZ performed the statistical analysis. CP, HYH and CLZ conceived of
the study and participated in its design as well as coordination and helped
to write and revise the manuscript. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The ethical approval is not necessary for the meta-analysis of the published
studies.
Author details
1Department of Orthopedic, Xiangya Hospital, Central South University,
No.87, Xiangya Road, Kaifu District, Changsha City, Hunan Province 410008,
China. 2Department of Oncology, Xiangya Hospital, Central South University,
Changsha, Hunan Province, China.
Received: 22 January 2016 Accepted: 23 September 2016
References
1. Leslie WD, Morin SN. Osteoporosis epidemiology 2013: implications for diagnosis,
risk assessment, and treatment. Curr Opin Rheumatol. 2014;26(4):440–6.
2. World Health Organization. Assessment of fracture risk and its application to
screening for postmenopausal osteoporosis. Report of a WHO Study Group.
World Health Organ Tech Rep Ser. 1994;843:1–129.
3. Cauley JA. Public health impact of osteoporosis. J Gerontol A Biol Sci Med
Sci. 2013;68(10):1243–51.
4. Wade SW, Strader C, Fitzpatrick LA, Anthony MS, O’Malley CD. Estimating
prevalence of osteoporosis: examples from industrialized countries. Arch
Osteoporos. 2014;9:182.
5. US OOTS. Bone health and osteoporosis: a report of the surgeon general.
Rockville: Office of the Surgeon General (US); 2004.
Chen et al. BMC Public Health  (2016) 16:1039 Page 10 of 11
6. Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J,
McCloskey EV, Jonsson B, Kanis JA. Osteoporosis in the European Union:
a compendium of country-specific reports. Arch Osteoporos. 2013;8:137.
7. Handa R, Ali KA, Maalouf G. Osteoporosis in developing countries. Best Pract
Res Clin Rheumatol. 2008;22(4):693–708.
8. World Health Organization. The World Health Report 1997–conquering
suffering, enriching humanity. World Health Forum. 1997;18(3-4):248–260.
9. Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL. Impact of
osteoporosis treatment adherence on fracture rates in North America and
Europe. The American journal of medicine.2009;122(2 Suppl):S3–13.
10. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay
R. Clinician’s guide to prevention and treatment of osteoporosis.
Osteoporos Int. 2014;25(10):2359–81.
11. Wiren KM, Toombs AR, Semirale AA, Zhang X. Osteoblast and osteocyte
apoptosis associated with androgen action in bone: requirement of
increased Bax/Bcl-2 ratio. Bone. 2006;38(5):637–51.
12. Zhang Z, Ho SC, Chen Z, Zhang C, Chen Y. Reference values of bone
mineral density and prevalence of osteoporosis in Chinese adults.
Osteoporos Int. 2014;25(2):497–507.
13. Wang Y, Tao Y, Hyman ME, Li J, Chen Y. Osteoporosis in china. Osteoporos
Int. 2009;20(10):1651–62.
14. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. J Clin
Epidemiol. 2009;62(10):1006–12.
15. Rostom A, Dube C, Cranney A, Saloojee N, Sy R, Garritty C, Sampson M,
Zhang L, Yazdi F, Mamaladze V, et al. Celiac disease. Evid Rep Technol
Assess (Summ). 2004;104:1–6.
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials.
1986;7(3):177–88.
17. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis.
Stat Med. 2002;21(11):1539–58.
18. Cheng XG, Yang DZ, Zhou Q, Zhuo TJ, Zhang HC, Xiang J, Wang HF, Ou PZ,
Liu JL, Xu L, et al. Age-related bone mineral density, bone loss rate,
prevalence of osteoporosis, and reference database of women at multiple
centers in China. J Clin Denestom. 2007;10(3):276–84.
19. Park EJ, Joo IW, Jang MJ, Kim YT, Oh K, Oh HJ. Prevalence of osteoporosis in
the Korean population based on Korea National Health and Nutrition
Examination Survey (KNHANES), 2008-2011. Yonsei Med J. 2014;55(4):1049–57.
20. Eisman J, Clapham S, Kehoe L. Osteoporosis prevalence and levels of
treatment in primary care: the Australian BoneCare Study. J Bone Miner Res.
2004;19(12):1969–75.
21. Siris ES, Brenneman SK, Barrett-Connor E, Miller PD, Sajjan S, Berger ML, Chen YT.
The effect of age and bone mineral density on the absolute, excess, and relative
risk of fracture in postmenopausal women aged 50-99: results from the National
Osteoporosis Risk Assessment (NORA). Osteoporos Int. 2006;17(4):565–74.
22. Irani AD, Poorolajal J, Khalilian A, Esmailnasab N, Cheraghi Z. Prevalence of
osteoporosis in Iran: A meta-analysis. J Res Med Sci. 2013;18(9):759–66.
23. Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, Dawson-Hughes
B. The recent prevalence of osteoporosis and low bone mass in the United
States based on bone mineral density at the femoral neck or lumbar spine.
J Bone Miner Res. 2014;29(11):2520–6.
24. Sinnesael M, Claessens F, Boonen S, Vanderschueren D. Novel insights in
the regulation and mechanism of androgen action on bone. Curr Opin
Endocrinol Diabetes Obes. 2013;20(3):240–4.
25. Carvalho M, Kulak CA, Borba VZ. Prevalence of hypercalciuria in postmenopausal
women with osteoporosis. Arq Bras Endocrinol Metabol. 2012;56(1):1–5.
26. Fujiwara S. Effectiveness of screening for osteoporosis by bone density
measurement for the prevention of fractures: a review of the evidence.
Nihon Eiseigaku Zasshi. 2003;58(3):338–46.
27. McGuire S. Institute of Medicine. 2009. School meals: building blocks for healthy
children. Washington, DC: The National Academies Press. Adv Nutr. 2011;2(1):64–5.
28. Muraki S, Yamamoto S, Ishibashi H, Oka H, Yoshimura N, Kawaguchi H,
Nakamura K. Diet and lifestyle associated with increased bone mineral
density: cross-sectional study of Japanese elderly women at an osteoporosis
outpatient clinic. J Orthop Sci. 2007;12(4):317–20.
29. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects.
J Clin Invest. 2005;115(12):3318–25.
30. Nguyen TV, Center JR, Eisman JA. Osteoporosis: underrated,
underdiagnosed and undertreated. Med J. 2004;180(5 Suppl):S18–22.
31. Xinhua: China to allow two children for all couples, 2015: 2015. http://news.
xinhuanet.com/english/2015-10/29/c_134763749.htm. Accessed 27 Nov 2015.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Chen et al. BMC Public Health  (2016) 16:1039 Page 11 of 11
